vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Solstice Advanced Materials Inc. (SOLS). Click either name above to swap in a different company.
Solstice Advanced Materials Inc. is the larger business by last-quarter revenue ($991.0M vs $722.5M, roughly 1.4× Amneal Pharmaceuticals, Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs 8.6%, a 2.2% gap on every dollar of revenue. On growth, Solstice Advanced Materials Inc. posted the faster year-over-year revenue change (10.0% vs 3.9%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Solstice Advanced Materials Inc. is a specialty advanced materials provider that develops, produces and distributes high-performance functional materials for renewable energy systems, consumer electronics, industrial manufacturing and advanced automotive sectors. The company focuses on material solutions that boost product durability, energy efficiency and operational performance for its global clients.
AMRX vs SOLS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $991.0M |
| Net Profit | $78.0M | $85.0M |
| Gross Margin | 44.3% | — |
| Operating Margin | 19.6% | — |
| Net Margin | 10.8% | 8.6% |
| Revenue YoY | 3.9% | 10.0% |
| Net Profit YoY | 410.5% | -36.6% |
| EPS (diluted) | $0.19 | $0.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $991.0M | ||
| Q4 25 | $814.3M | — | ||
| Q3 25 | $784.5M | $969.0M | ||
| Q2 25 | $724.5M | — | ||
| Q1 25 | $695.4M | — | ||
| Q4 24 | $730.5M | — | ||
| Q3 24 | $702.5M | $907.0M | ||
| Q2 24 | $701.8M | — |
| Q1 26 | $78.0M | $85.0M | ||
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | $-35.0M | ||
| Q2 25 | $22.4M | — | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | $152.0M | ||
| Q2 24 | $6.0M | — |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | 32.0% | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | 36.6% | ||
| Q2 24 | 35.6% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | 17.9% | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | 21.7% | ||
| Q2 24 | 13.6% | — |
| Q1 26 | 10.8% | 8.6% | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | -3.6% | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | 16.8% | ||
| Q2 24 | 0.9% | — |
| Q1 26 | $0.19 | $0.53 | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $197.7M | $642.0M |
| Total DebtLower is stronger | — | $2.0B |
| Stockholders' EquityBook value | — | $1.5B |
| Total Assets | $3.5B | $5.7B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $197.7M | $642.0M | ||
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | $417.0M | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — |
| Q1 26 | — | $2.0B | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-70.8M | — | ||
| Q3 25 | $-109.5M | $3.2B | ||
| Q2 25 | $-112.1M | — | ||
| Q1 25 | $-131.7M | — | ||
| Q4 24 | $-109.3M | — | ||
| Q3 24 | $-93.4M | $3.2B | ||
| Q2 24 | $-57.5M | — |
| Q1 26 | $3.5B | $5.7B | ||
| Q4 25 | $3.7B | — | ||
| Q3 25 | $3.6B | $5.2B | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.5B | — |
| Q1 26 | — | 1.34× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $199.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 7.6% |
| Cash ConversionOCF / Net Profit | — | 2.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $199.0M | ||
| Q4 25 | $130.3M | — | ||
| Q3 25 | $118.5M | $289.0M | ||
| Q2 25 | $83.8M | — | ||
| Q1 25 | $7.4M | — | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $141.8M | — | ||
| Q2 24 | $39.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | $41.0M | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | 4.2% | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
| Q1 26 | — | 7.6% | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | 25.6% | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
| Q1 26 | — | 2.34× | ||
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
Segment breakdown not available.
SOLS
| Product sales | $915.0M | 92% |
| Service sales | $77.0M | 8% |
